First Tracks Biotherapeutics Raises $145M Ahead of AnaptysBio Spin-Off
Event summary
- First Tracks Biotherapeutics, a planned spin-off of AnaptysBio, secured $145M in private placement, including $80M in gross proceeds from the sale of 5.79M shares at $13.81 per share.
- The transaction is expected to close upon completion of the spin-off on April 20, 2026.
- Proceeds will fund clinical development of ANB033, a CD122 antagonist.
- Investors include 683 Capital Partners, Adage Capital Partners, and other institutional investors.
The big picture
The $145M private placement underscores investor confidence in First Tracks Biotherapeutics' pipeline, particularly ANB033. The spin-off reflects a strategic shift in AnaptysBio's portfolio management, aligning with broader industry trends of focused biotech spin-offs to streamline development and enhance shareholder value. The deal size and investor lineup signal strong backing for the new entity's clinical ambitions.
What we're watching
- Execution Risk
- Whether First Tracks Biotherapeutics can efficiently transition from AnaptysBio and maintain momentum in clinical development.
- Market Dynamics
- How the $180M cash runway positions First Tracks Biotherapeutics against competitors in the CD122 antagonist space.
- Investor Confidence
- The pace at which new and existing investors continue to support First Tracks Biotherapeutics post-spin-off.
Related topics